Cost and supply considerations for antibody therapeutics
Monoclonal antibodies (mAbs) and mAb-derived biologics have achieved substantial success across various therapeutic areas over recent decades. Their widespread adoption, however, remains constrained due to high prices and challenges in supply. Here, we examine the general price and cost structure of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2451789 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593989758353408 |
|---|---|
| author | Chun Chen Zoe Garcia David Chen Hong Liu Piper Trelstad |
| author_facet | Chun Chen Zoe Garcia David Chen Hong Liu Piper Trelstad |
| author_sort | Chun Chen |
| collection | DOAJ |
| description | Monoclonal antibodies (mAbs) and mAb-derived biologics have achieved substantial success across various therapeutic areas over recent decades. Their widespread adoption, however, remains constrained due to high prices and challenges in supply. Here, we examine the general price and cost structure of mAbs and mAb-derived therapeutics and identify directions to improve affordability and strategies to ensure supply. Mainstream and emerging biomanufacturing formats and their implications on cost and supply are discussed. We also summarize modeling tools used across industry for process economics analysis, emphasizing the importance of this assessment throughout the product development lifecycle. A comprehensive understanding of cost and supply scenarios will empower industry players to thrive despite competition, navigate supply challenges, and broaden access to mAb therapeutics for more patients. |
| format | Article |
| id | doaj-art-3dfa64394b3c49aeb61a6fc66f0757a0 |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-3dfa64394b3c49aeb61a6fc66f0757a02025-01-20T06:40:47ZengTaylor & Francis GroupmAbs1942-08621942-08702025-12-0117110.1080/19420862.2025.2451789Cost and supply considerations for antibody therapeuticsChun Chen0Zoe Garcia1David Chen2Hong Liu3Piper Trelstad4Chemistry, Manufacturing and Controls, Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USAChemistry, Manufacturing and Controls, Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USAChemistry, Manufacturing and Controls, Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USAChemistry, Manufacturing and Controls, Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USAChemistry, Manufacturing and Controls, Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USAMonoclonal antibodies (mAbs) and mAb-derived biologics have achieved substantial success across various therapeutic areas over recent decades. Their widespread adoption, however, remains constrained due to high prices and challenges in supply. Here, we examine the general price and cost structure of mAbs and mAb-derived therapeutics and identify directions to improve affordability and strategies to ensure supply. Mainstream and emerging biomanufacturing formats and their implications on cost and supply are discussed. We also summarize modeling tools used across industry for process economics analysis, emphasizing the importance of this assessment throughout the product development lifecycle. A comprehensive understanding of cost and supply scenarios will empower industry players to thrive despite competition, navigate supply challenges, and broaden access to mAb therapeutics for more patients.https://www.tandfonline.com/doi/10.1080/19420862.2025.2451789Antibodybiomanufacturingcost of goodseconomic analysissupply |
| spellingShingle | Chun Chen Zoe Garcia David Chen Hong Liu Piper Trelstad Cost and supply considerations for antibody therapeutics mAbs Antibody biomanufacturing cost of goods economic analysis supply |
| title | Cost and supply considerations for antibody therapeutics |
| title_full | Cost and supply considerations for antibody therapeutics |
| title_fullStr | Cost and supply considerations for antibody therapeutics |
| title_full_unstemmed | Cost and supply considerations for antibody therapeutics |
| title_short | Cost and supply considerations for antibody therapeutics |
| title_sort | cost and supply considerations for antibody therapeutics |
| topic | Antibody biomanufacturing cost of goods economic analysis supply |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2025.2451789 |
| work_keys_str_mv | AT chunchen costandsupplyconsiderationsforantibodytherapeutics AT zoegarcia costandsupplyconsiderationsforantibodytherapeutics AT davidchen costandsupplyconsiderationsforantibodytherapeutics AT hongliu costandsupplyconsiderationsforantibodytherapeutics AT pipertrelstad costandsupplyconsiderationsforantibodytherapeutics |